However, the FDA-approved SRC inhibitor Dasatinib shows very limited efficacy in HNSCC clinical trials, even though Dasatinib can completely inhibit SRC in the laboratory setting. The gene discussed is SRC; the disease is head and neck squamous cell carcinoma.